Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection

Figure 1 Diagnosis and management of metabolic dysfunction-associated steatotic liver disease in patients with chronic hepatitis B[79]. MASLD: Metabolic dysfunction-associated steatotic liver disease; CHB: Chronic hepatitis B; CMRF: Cardiometabolic risk factor; CAP: Controlled attenuation parameter; MRI-PDFF: Magnetic resonance imaging-proton density fat fraction; NILDA: Non-invasive liver disease assessment; FIB-4: Fibrosis-4; LSM: Liver stiffness measurement; ELF: Enhanced liver fibrosis; T2DM: Type 2 diabetes mellitus. Adapted from: Kanwal et al[79]. Citation: Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2021; 161: 1657-1669. Copyright©2021 by the AGA Institute. Published by Elsevier Inc. The authors have obtained the permission for figure using (Supplementary material).